EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Safety of belimumab during pregnancy: associations with maternal and fetal or newborn adverse outcomes based on FAERS data

Yujie Lin, Jing Yao iD

Therapeutic Advances in Drug Safety · 2026-06 · 17

DOI: 10.1177/20420986261460168 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Drug Safety, online erschienen am 18.06.2026. Verfasst von Yujie Lin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, Jiangsu, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Belimumab is a biologic agent used in the treatment of systemic lupus erythematosus (SLE). However, its safety profile during pregnancy has not been fully established, and real-world evidence regarding its association with adverse pregnancy outcomes remains limited.

Objectives

To evaluate the safety of belimumab during pregnancy and explore its potential associations with maternal and fetal/neonatal adverse events.

Design

Retrospective pharmacovigilance study.

Methods

Disproportionality analysis of pregnancy-related individual case safety reports (ICSRs) from the FDA Adverse Event Reporting System (FAERS), Q2 2011–Q4 2024. Pregnancy-related cases were identified using Standardized MedDRA Queries. Belimumab was the primary suspected drug, with hydroxychloroquine and mycophenolate mofetil as negative and positive controls, respectively. Signal detection employed the reporting odds ratio (ROR); stratified analyses assessed potential confounding factors.

Results

A total of 263,400 ICSRs was identified, including 537 belimumab, 1033 hydroxychloroquine, and 1039 mycophenolate mofetil. Most belimumab-related cases were reported from North America (78.40%), with SLE as the primary indication (71.88%). Disproportionality analysis revealed significant reporting of abortion (ROR 2.15, 95% confidence interval (CI) 1.76–2.63), hypertensive disorders of pregnancy (ROR 2.20, 95% CI 1.32–3.66), and pregnancy-related hemorrhagic complications (ROR 2.19, 95% CI 1.09–4.40), but not for stillbirth, preterm birth, or congenital malformations. A neonatal respiratory disorder signal was also observed (ROR 6.50, 95% CI 2.90–14.53). The hypertensive disorder signal was amplified with concomitant glucocorticoid use, suggesting confounding by disease severity. Mycophenolate mofetil, as a positive control, generated expected signals for adverse pregnancy outcomes and congenital anomalies, validating method sensitivity.

Conclusion

Belimumab exposure during pregnancy is not associated with a significantly elevated risk of stillbirth, preterm birth, or overall congenital malformations. Conversely, disproportionality signals were detected for abortion, hypertensive disorders of pregnancy, hemorrhagic complications, and neonatal respiratory disorders. These signals warrant cautious interpretation, as they may partially reflect the elevated baseline risk intrinsic to the high-risk SLE patient population.

Schlagwörter

Stichwörter der Autor:innen

FAERS databaseadverse pregnancy outcomesbelimumabpharmacovigilancesystemic lupus erythematosus

Autor:innen und Institutionen

  • Department of Pharmacy, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, Jiangsu, China.
  • Department of Pharmacy, The Affiliated Taizhou People's Hospital of Nanjing Medical University, No. 366 Taihu Road, Pharmaceutical High-Tech Zone, Taizhou, Jiangsu Province 225300, China.

ORCID-Profile: Jing Yao

Zitieren

APA

Lin, Y., & Yao, J. (2026). Safety of belimumab during pregnancy: associations with maternal and fetal or newborn adverse outcomes based on FAERS data. Therapeutic Advances in Drug Safety, 17. https://doi.org/10.1177/20420986261460168

Vancouver

Lin Y, Yao J. Safety of belimumab during pregnancy: associations with maternal and fetal or newborn adverse outcomes based on FAERS data. Therapeutic Advances in Drug Safety. 2026;17. doi:10.1177/20420986261460168

BibTeX
@article{Lin2026,
  author = {Lin, Yujie and Yao, Jing},
  title = {Safety of belimumab during pregnancy: associations with maternal and fetal or newborn adverse outcomes based on FAERS data},
  journal = {Therapeutic Advances in Drug Safety},
  year = {2026},
  volume = {17},
  doi = {10.1177/20420986261460168}
}
Kostenlos starten →